Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration.
Drug development in pediatric oncology has been reviewed, concentrating on overall development issues and COG studies of cytotoxic compounds. A variety of interesting molecules with more specific targeting are becoming available. The challenges that remain include the availability of such compounds for pediatric trial and their study in a timely fashion, and the subsequent incorporation of the new agents into more up-front regimens, with the ultimate shared goal of curing more children with less toxicity.
Bernstein
M L
ML
Service of Hematology-Oncology, Sainte-Justine Hospital, Department of Pediatrics, University of Montreal, Montreal, Québec, Canada.
Reaman
G H
GH
Hirschfeld
S
S
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D015195:Drug Design; D004992:Ethics, Medical; D005568:Forms and Records Control; D006801:Humans; D007223:Infant; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D020714:Maximum Tolerated Dose; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy*; D018579:Patient Selection; D012449:Safety; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic